Is Waters Corporation (WAT) A Good Stock To Buy Now?

Pixabay/Public Domain

Waters Corporation provides analytical workflow solutions successful Asia, the Americas, and Europe. WAT precocious experienced a crisp selloff pursuing its Q4 2025 results and the closing of its transformative merger with BD’s Biosciences and Diagnostic Solutions division, creating a compelling introduction constituent into a high-quality analytical instruments business.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Despite near-term concerns astir integration, the halfway Waters concern remains fundamentally strong, generating $762 cardinal successful operating currency travel with industry-leading margins and a resilient exemplary built connected liquid chromatography, wide spectrometry, and thermal investigation tools. The institution benefits from a highly recurring gross base, with 57% of income derived from consumables and work contracts, and a sticky lawsuit basal led by pharma and biopharma clients, which relationship for 58% of revenue.

Financially, Waters has demonstrated accordant profitability, with FY2025 non-GAAP EPS increasing 11% to $13.13 and escaped currency travel conversion exceeding 100% of nett income, highlighting exceptional currency generation. At existent levels, the banal trades astatine astir 24x earnings, a meaningful discount to its humanities 38–42x scope and beneath assemblage averages, contempt maintaining ~59% gross margins and beardown liquidity metrics, including a 1.53x existent ratio.

The BD merger much than doubles gross and introduces important semipermanent synergies, positioning the combined entity for 10%+ EPS maturation and important standard benefits. While integration and elevated leverage contiguous short-term risks, robust currency flows supply a wide way to deleveraging. With secular tailwinds from pharma innovation, instrumentality replacement cycles, and expanding planetary demand, Waters offers an charismatic risk-reward profile, wherever palmy execution could thrust meaningful aggregate enlargement and sustained shareholder returns.

Previously, we covered a bullish thesis connected Thermo Fisher Scientific Inc. (TMO) by Kontra successful October 2024, which highlighted the company’s positioning arsenic a prime compounder driven by its diversified beingness sciences portfolio and beardown competitory advantages. TMO’s banal terms has depreciated by astir 23.11% since our coverage. The Wealth Dynasty Report shares a akin presumption but emphasizes connected Waters Corporation’s discounted valuation and integration-driven upside.